Topline PhIII data bode well as Lilly's dulaglutide girds for diabetes battle
This article was originally published in Scrip
Eli Lilly reported topline data from three Phase III clinical trials that showed the higher of two once-weekly doses for the long-acting glucagon-like peptide 1 (GLP-1) analogue dulaglutide (LY2189265) met the trials' primary endpoints, while both the 0.75mg and 1.5mg doses were statistically superior to three other drugs in the treatment of type 2 diabetes.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.